Aging and cancer最新文献

筛选
英文 中文
Barriers to access cancer-related services for men in high-income countries: A narrative review looking beyond socioeconomic disadvantages 高收入国家男性获得癌症相关服务的障碍:超越社会经济劣势的叙述性综述
Aging and cancer Pub Date : 2022-12-18 DOI: 10.1002/aac2.12059
Ali Zafar, Franziska Baessler, Andreas Ihrig, Gwendolyn Mayer, Till Johannes Bugaj, Imad Maatouk, Jens Staeudle, Hans-Christoph Friederich, Jobst-Hendrik Schultz
{"title":"Barriers to access cancer-related services for men in high-income countries: A narrative review looking beyond socioeconomic disadvantages","authors":"Ali Zafar,&nbsp;Franziska Baessler,&nbsp;Andreas Ihrig,&nbsp;Gwendolyn Mayer,&nbsp;Till Johannes Bugaj,&nbsp;Imad Maatouk,&nbsp;Jens Staeudle,&nbsp;Hans-Christoph Friederich,&nbsp;Jobst-Hendrik Schultz","doi":"10.1002/aac2.12059","DOIUrl":"10.1002/aac2.12059","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Cancer screening programs are routinely available in high-income countries, but participation rates are low, especially among men. This narrative review aims to identify male-specific access barriers to cancer-related healthcare in high-income countries that offer statutory insurance/subsidized health care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched PubMed, Science Direct, and Web of Science for peer-reviewed journal articles published within the past 10 years on cancer healthcare access, help-seeking behavior, and men. Step-wise screening of title, abstract, and full text resulted in 23 studies that fit the selection criteria for findings in high-income countries. The results were analyzed descriptively using qualitative thematic synthesis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the reviewed studies, barriers for men in accessing cancer-related healthcare offers could be broadly categorized under sociocultural norms, personal behaviors, and structural problems. The most common barriers were related to sociocultural influences and included notions of masculinity, distrust in the medical system, and personnel/social commitments. Major personal barriers included fear of getting cancer or screening methods, lack of awareness about cancer, and problems in communication with healthcare professionals. Accessibility and lack of insurance were reported as common structural barriers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The reluctance of men in approaching medical help was rooted in sociocultural norms of traditional masculinity with direct and indirect consequences such as fear, lack of awareness, distrust of medical personnel, and problems in communicating with healthcare professionals. Gender-specific, male-oriented information via digital, anonymous interventions may be helpful for increasing participation of men in cancer care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 3-4","pages":"147-160"},"PeriodicalIF":0.0,"publicationDate":"2022-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aac2.12059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42484978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The impact of Omicron pandemic and COVID-19 vaccination on the pancreatic adenocarcinoma patients 奥密克戎大流行和新冠肺炎疫苗接种对胰腺癌患者的影响。
Aging and cancer Pub Date : 2022-12-08 DOI: 10.1002/aac2.12056
Ningzhen Fu, Yu Jiang, Zhiwei Xu, Meng Yang, Chenghong Peng, Xiaxing Deng, Shulin Zhao, Baiyong Shen
{"title":"The impact of Omicron pandemic and COVID-19 vaccination on the pancreatic adenocarcinoma patients","authors":"Ningzhen Fu,&nbsp;Yu Jiang,&nbsp;Zhiwei Xu,&nbsp;Meng Yang,&nbsp;Chenghong Peng,&nbsp;Xiaxing Deng,&nbsp;Shulin Zhao,&nbsp;Baiyong Shen","doi":"10.1002/aac2.12056","DOIUrl":"10.1002/aac2.12056","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The coronavirus disease 2019 (COVID-19) pandemic resulted in enormous medical and economic burden worldwide during the past 3 years. The vaccination was deemed the effective option to prevent the severe symptoms, and especially recommended among cancer patients. Shanghai experienced the first lockdown during the recent Omicron pandemic since 2019. How patients with pancreatic adenocarcinoma (PAC) suffered from the pandemic and how vaccination influenced their oncological outcomes were unexplored yet.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>The retrospective study was carried out in a high-volume referral center including 1157 consecutively enrolled patients with PAC experiencing the COVID-19 pandemic. The primary outcome was the overall survival (OS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Limited postoperative patients (9.21%) received the vaccination. The lockdown in Shanghai (April to May, 2022) was not observed impacting the survival prognoses of patients with PAC. Though vaccination was not significantly associated with OS itself (adjusted hazard ratio (aHR): 2.032 [0.940–4.391], <i>p =</i> 0.071), it was discovered to synergistically improve the chemotherapy effect in the multivariate analyses (interaction <i>p =</i> 0.023).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The vaccination itself did not influence the survival prognoses of patients with PAC. A potential positive interaction was observed between chemotherapy and vaccination despite the limited follow-up time. The postoperative patients should consider the vaccination more. The patients with PAC did not suffer worse prognostic outcomes from the strict sanitary policy during the wave of COVID-19 pandemic in Shanghai.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 3-4","pages":"161-168"},"PeriodicalIF":0.0,"publicationDate":"2022-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10590387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary extranodal diffuse large B-cell lymphoma: Molecular features, treatment, and prognosis 原发性结外弥漫性大B细胞淋巴瘤:分子特征、治疗和预后
Aging and cancer Pub Date : 2022-11-27 DOI: 10.1002/aac2.12058
Si-Yuan Chen, Meng-Meng Ji, Peng-Peng Xu, Wei-Li Zhao
{"title":"Primary extranodal diffuse large B-cell lymphoma: Molecular features, treatment, and prognosis","authors":"Si-Yuan Chen,&nbsp;Meng-Meng Ji,&nbsp;Peng-Peng Xu,&nbsp;Wei-Li Zhao","doi":"10.1002/aac2.12058","DOIUrl":"10.1002/aac2.12058","url":null,"abstract":"<p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and represents a heterogeneous entity. One-third of DLBCL arises from extranodal organs and its prognosis often varies with regard to the sites involved. Molecular features are important to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Extranodal DLBCLs originated from the breast, skin, uterus, immune-privileged sites such as the central nervous system and testes, often show a high proportion of non-germinal center B-cell-like (non-GCB) phenotypes, with a high frequency of <i>MYD88</i><i>/</i><i>CD79B</i> mutations. In contrast, extranodal DLBCLs originated from the thyroid gland and stomach show a relatively low proportion of non-GCB phenotype, with a considerably excellent prognosis. Immunochemotherapy with rituximab is the standard of care in both nodal and extranodal DLBCLs. However, approximately 40% of the patients experience treatment failure. It is critical to optimize the treatment strategy, including radiotherapy, autologous stem cell transplantation and targeted therapy according to the clinical characteristics and molecular heterogeneity. In this review, we present an overview of the key molecular pathways, prognosis assessment and innovative therapies in primary extranodal DLBCLs.</p>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 3-4","pages":"133-146"},"PeriodicalIF":0.0,"publicationDate":"2022-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aac2.12058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41409097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer and aging: A call to action 癌症与衰老:行动呼吁。
Aging and cancer Pub Date : 2022-07-12 DOI: 10.1002/aac2.12055
Dejana Braithwaite, Stephen Anton, Supriya Mohile, James DeGregori, Nancy Gillis, Daohong Zhou, Shirley Bloodworth, Marco Pahor, Jonathan Licht
{"title":"Cancer and aging: A call to action","authors":"Dejana Braithwaite,&nbsp;Stephen Anton,&nbsp;Supriya Mohile,&nbsp;James DeGregori,&nbsp;Nancy Gillis,&nbsp;Daohong Zhou,&nbsp;Shirley Bloodworth,&nbsp;Marco Pahor,&nbsp;Jonathan Licht","doi":"10.1002/aac2.12055","DOIUrl":"10.1002/aac2.12055","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The intersection of cancer and aging is an emerging public health challenge in developed countries because of the aging and expansion of the population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We convened a panel of experts to share their insights on this topic at the inaugural University of Florida Health Cancer Center's (UFHCC's) Cancer and Aging Symposium, which was held virtually in February 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We featured presentations from four leading scientists, whose research spans multiple disciplines including basic science, translational research, geriatric oncology, and population science.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Each speaker offered their unique perspective and insight on the intersection between cancer and aging and discussed their current and ongoing research in this field. In addition to this panel of experts, scientists from the National Institutes of Health and the National Cancer Institute, as well as a UFHCC-affiliated citizen scientist, shared their perspectives on strategies to move the field forward. Some of the key open questions and opportunities for future research offered by these presenters in aging and cancer include but are not limited to infusing health disparities research into the field of cancer and aging, assessing the value of geriatric assessment in identifying early vulnerabilities that may affect response to emerging cancer therapies in older patients, and assessing biological age and other biomarkers (e.g., clonal hematopoiesis) in relation to clinical endpoints and the development of primary, secondary, and tertiary cancer prevention interventions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Research is needed to accelerate knowledge regarding the dynamic interplay of cancer and aging and optimize care in diverse older adults to achieve equity in cancer outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 2","pages":"87-94"},"PeriodicalIF":0.0,"publicationDate":"2022-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9190117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Aging and biliary tract cancers: Epidemiology, molecular biology, and clinical practice 衰老与胆道癌:流行病学、分子生物学和临床实践
Aging and cancer Pub Date : 2022-06-13 DOI: 10.1002/aac2.12054
Xiaoling Weng, Xiaoling Song, Rong Shao, Fatao Liu, Yingbin Liu
{"title":"Aging and biliary tract cancers: Epidemiology, molecular biology, and clinical practice","authors":"Xiaoling Weng,&nbsp;Xiaoling Song,&nbsp;Rong Shao,&nbsp;Fatao Liu,&nbsp;Yingbin Liu","doi":"10.1002/aac2.12054","DOIUrl":"10.1002/aac2.12054","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 \u0000 <p>Biliary tract cancer (BTC) that contains cholangiocarcinoma, gallbladder cancer, and ampullary cancer is highly malignant and mostly diagnosed in elderly patients. Over the past decades, human life has globally risen; thus, aging emerges as the primary risk factor for BTC. However, an effective treatment for this vulnerable population remains a large clinical challenge. As a result, the incidence and mortality of TBC remains high. Here, we discuss the potential link between aging and BTC from the aspects of molecular and cellular mechanisms, surgical resection, and chemotherapy. In addition, we update a number of clinical trials that are currently ongoing in elderly patients. The overview of BTC in elderly patients is expected to help develop a new therapeutic strategy tailored to this elderly population, ultimately improving their life quality.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 2","pages":"95-104"},"PeriodicalIF":0.0,"publicationDate":"2022-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aac2.12054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44077661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Another wrinkle with age: Aged collagen and intra-peritoneal metastasis of ovarian cancer 另一个与年龄有关的问题:老化的胶原蛋白和卵巢癌腹膜内转移
Aging and cancer Pub Date : 2022-04-19 DOI: 10.1002/aac2.12049
Elizabeth I. Harper, Tyvette S. Hilliard, Emma F. Sheedy, Preston Carey, Paul Wilkinson, Michael D. Siroky, Jing Yang, Elizabeth Agadi, Annemarie K. Leonard, Ethan Low, Yueying Liu, Arya Biragyn, Christina M. Annunziata, Mary Sharon Stack
{"title":"Another wrinkle with age: Aged collagen and intra-peritoneal metastasis of ovarian cancer","authors":"Elizabeth I. Harper,&nbsp;Tyvette S. Hilliard,&nbsp;Emma F. Sheedy,&nbsp;Preston Carey,&nbsp;Paul Wilkinson,&nbsp;Michael D. Siroky,&nbsp;Jing Yang,&nbsp;Elizabeth Agadi,&nbsp;Annemarie K. Leonard,&nbsp;Ethan Low,&nbsp;Yueying Liu,&nbsp;Arya Biragyn,&nbsp;Christina M. Annunziata,&nbsp;Mary Sharon Stack","doi":"10.1002/aac2.12049","DOIUrl":"10.1002/aac2.12049","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Age is the most significant risk factor for ovarian cancer (OvCa), the deadliest gynecologic malignancy. Metastasizing OvCa cells adhere to the omentum, a peritoneal structure rich in collagen, adipocytes, and immune cells. Ultrastructural changes in the omentum and the omental collagen matrix with aging have not been evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The aim of this study was to test the hypothesis that age-related changes in collagen in the ovarian tumor microenvironment promote OvCa metastatic success in the aged host.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods/Results</h3>\u0000 \u0000 <p>Young (3–6 months) and aged mice (20–23 months) were used to study the role of aging in metastatic success. Intra-peritoneal (IP) injection of ID8<i>Trp53<sup>–/–</sup></i> OvCa cells showed enhanced IP dissemination in aged versus young mice. In vitro assays using purified collagen demonstrated reduced collagenolysis of aged fibers, as visualized using scanning electron microscopy (SEM) and quantified with a hydroxyproline release assay. Omental tumors in young and aged mice showed similar collagen deposition; however enhanced intra-tumoral collagen remodeling was seen in aged mice probed with a biotinylated collagen hybridizing peptide (CHP). In contrast, second harmonic generation (SHG) microscopy showed significant differences in collagen fiber structure and organization in omental tissue, and SEM demonstrated enhanced omental fenestration in aged omenta. Combined SHG and Alexa Fluor-CHP microscopy in vivo demonstrated that peri-tumoral collagen was remodeled more extensively in young mice. This collagen population represents truly aged host collagen, in contrast to intra-tumoral collagen that is newly synthesized, likely by cancer-associated fibroblasts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our results demonstrate that tumors in an aged host can grow with minimal collagen remodeling, while tumors in the young host must remodel peri-tumoral collagen to enable effective proliferation, providing a mechanism whereby age-induced ultrastructural changes in collagen and collagen-rich omenta establish a permissive premetastatic niche contributing to enhanced OvCa metastatic success in the aged host.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 2","pages":"116-129"},"PeriodicalIF":0.0,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518742/pdf/nihms-1793530.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9549824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis 老年新诊断晚期膀胱癌患者的治疗模式:SEER数据集分析
Aging and cancer Pub Date : 2022-03-27 DOI: 10.1002/aac2.12048
Elizabeth R. Kessler, Sarah J. Schmiege, Megan Eguchi, Sarguni Singh, Stacy M. Fischer
{"title":"Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis","authors":"Elizabeth R. Kessler,&nbsp;Sarah J. Schmiege,&nbsp;Megan Eguchi,&nbsp;Sarguni Singh,&nbsp;Stacy M. Fischer","doi":"10.1002/aac2.12048","DOIUrl":"10.1002/aac2.12048","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Bladder cancer is one of the top 10 cancers diagnosed in Americans with a median age of 73. This is the patient population that tends to be older with multiple medical conditions, and previously described variability in treatment in the earlier stages of the disease. This study aimed to evaluate the first-line therapeutic choices for older adults newly diagnosed with advanced bladder cancer. In addition, this work evaluated predictors of response as well as the role of events of functional importance in relation to treatment assignment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A population-based cohort study was conducted using the SEER-Medicare database of patients with advanced stage bladder cancer not eligible for curative intent therapy between 2010 and 2013. Patient groups of interest were compared via univariate and multivariate associations. Additionally, a latent class analysis was applied to identify classes with similar features in reference to events of functional importance—events linked to the maintenance or improvement of physical function status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Within the sample, we noted that a minority of patients received a standard cisplatin-containing regimen (14.77%) and a majority did not receive any chemotherapy (59.69%). Most patients were over age 75. The adjusted odds ratio of no chemo versus cisplatin in patients aged 76 and older compared to patients 66–75 was 6.61 (4.79–9.13; <i>p</i> &lt; 0.0001). We applied latent class analysis methods to the dataset, and three classes demonstrated very low and moderate levels of functional events in the 12 months prior to a person's first outpatient visit for advanced bladder cancer care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with new diagnosis of advanced bladder cancer largely do not receive the recommended first-line systemic therapy of cisplatin chemotherapy, and a significant majority does not receive any treatment. When evaluating the association between class assignment and predictors of chemotherapy use, such as comorbidity and age, patients with “low usage overall” were more likely to receive chemotherapy. Yet even patients who received chemotherapy had some events of functional importance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 2","pages":"105-115"},"PeriodicalIF":0.0,"publicationDate":"2022-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/6f/nihms-1796828.PMC9894163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9913852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DNA damage response inhibition-based combination therapies in cancer treatment: Recent advances and future directions 基于DNA损伤反应抑制的癌症联合治疗:最新进展和未来方向
Aging and cancer Pub Date : 2022-03-07 DOI: 10.1002/aac2.12047
Tianen Chen, Suparat Tongpeng, Ziyi Lu, Win Topatana, Sarun Juengpanich, Shijie Li, Jiahao Hu, Jiasheng Cao, Cheeshin Lee, Yitong Tian, Mingyu Chen, Xiujun Cai
{"title":"DNA damage response inhibition-based combination therapies in cancer treatment: Recent advances and future directions","authors":"Tianen Chen,&nbsp;Suparat Tongpeng,&nbsp;Ziyi Lu,&nbsp;Win Topatana,&nbsp;Sarun Juengpanich,&nbsp;Shijie Li,&nbsp;Jiahao Hu,&nbsp;Jiasheng Cao,&nbsp;Cheeshin Lee,&nbsp;Yitong Tian,&nbsp;Mingyu Chen,&nbsp;Xiujun Cai","doi":"10.1002/aac2.12047","DOIUrl":"10.1002/aac2.12047","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>DNA molecules are subject to various lesions that can be detrimental to the cells. DNA damage response (DDR) pathways encompass a variety of mechanisms that cells employ in response to DNA damage. While DDR promotes genomic stability in normal cells, it also protects cancer cells from DNA lesions, particularly against exogenous DNA-damaging agents. Therefore, DDR pathways can be exploited to account for resistance to chemotherapy and radiotherapy and have the potential to be targeted in cancer treatment. Apart from the poly (ADP-ribose) polymerase (PARP) inhibitors used in BRCA-mutant cancers, other DDR inhibitors are being developed and tested in clinical trials. Based on the synthetic lethality theory, combination therapies utilizing DDR inhibitors have been explored and are currently undergoing clinical trials, with promising results in cancer treatment. Combination therapies typically employ a DDR inhibitor to sensitize cancer cells to traditional chemotherapeutic agents, radiotherapy, immunotherapy, and even PARP inhibitors. Herein, we focus on recent advances in DDR inhibitor-based combination therapies other than PARP inhibitors, explore the advantages and disadvantages of the strategies, and discuss the current challenges and future perspectives.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 1","pages":"44-67"},"PeriodicalIF":0.0,"publicationDate":"2022-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aac2.12047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48480462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice 免疫检查点表达及其与抗pd - l1免疫检查点阻断癌免疫治疗效果的关系
Aging and cancer Pub Date : 2022-02-25 DOI: 10.1002/aac2.12045
Myrna G. Garcia, Yilun Deng, Clare Murray, Ryan M Reyes, Alvaro Padron, Haiyan Bai, Aravind Kancharla, Harshita Gupta, Shai Shen-Orr, Tyler J. Curiel
{"title":"Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice","authors":"Myrna G. Garcia,&nbsp;Yilun Deng,&nbsp;Clare Murray,&nbsp;Ryan M Reyes,&nbsp;Alvaro Padron,&nbsp;Haiyan Bai,&nbsp;Aravind Kancharla,&nbsp;Harshita Gupta,&nbsp;Shai Shen-Orr,&nbsp;Tyler J. Curiel","doi":"10.1002/aac2.12045","DOIUrl":"10.1002/aac2.12045","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Aging is the biggest cancer risk, and immune checkpoint (IC) inhibition (ICI) is a revolutionary cancer immunotherapy approach. Nonetheless, there are limited preclinical/clinical data regarding aging effects on ICI outcomes or age effects on IC expression in different organs or tumors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Flow cytometry assessed IC on immune and non-immune cells in various organs in young and aged BL6 mice. Comparisons: aged versus young naïve WT versus interferon-γ<sup>KO</sup> mice and WT challenged with B16F10 melanoma and treated with αPD-1 or αPD-L1 ICI. We co-cultured young and aged T cells and myeloid cells in vitro and used OMIQ analyses to test cell–cell interactions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>αPD-1 ICI treated melanoma in young and aged hosts, whereas αPD-L1 ICI was only effective in young. We found considerable, previously undescribed age effects on expression of various IC molecules participating in the ICI treatment, including PD-1, PD-L1, PD-L2, and CD80, in distinct organs and in the tumor. These data help explain differential ICI efficacy in young and aged hosts. Host interferon-γ influenced age effects on IC expression in both directions depending on specific IC molecule and tissue. IC expression was further affected by tumor challenge on immune, non-immune, and tumor cells in tumor and other organs. In in vitro co-culture, αPD-1 versus αPD-L1 distinctly influenced polyclonal T cells in young versus aged, suggesting mechanisms for distinct age-related ICI outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Age affects IC expression on specific immune cells in an organ- and tissue-specific manner. ICs were generally higher on aged immune cells. High immune-cell PD-1 could help explain αPD-1 efficacy in aged. High co-expression of CD80 with PD-L1 on dendritic cells could help explain lack of αPD-L1 efficacy in aged hosts. Factors other than myeloid cells and interferon-γ also affect age-related IC expression and T cell function, meriting additional studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 1","pages":"68-83"},"PeriodicalIF":0.0,"publicationDate":"2022-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10849985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The critical function of metabolic reprogramming in cancer metastasis 代谢重编程在癌症转移中的关键作用
Aging and cancer Pub Date : 2022-02-23 DOI: 10.1002/aac2.12044
Sun-Zhe Xie, Jun-Jie Pan, Jian-Feng Xu, Wen-wei Zhu, Lun-Xiu Qin
{"title":"The critical function of metabolic reprogramming in cancer metastasis","authors":"Sun-Zhe Xie,&nbsp;Jun-Jie Pan,&nbsp;Jian-Feng Xu,&nbsp;Wen-wei Zhu,&nbsp;Lun-Xiu Qin","doi":"10.1002/aac2.12044","DOIUrl":"10.1002/aac2.12044","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Cancer metastasis is the leading cause of cancer-related death. It is a complex, inefficient, and multistep process related to poor prognosis and high mortality of patients. Increasing evidence has shown that metabolic programming is a recognized hallmarker of cancer, plays a critical role in cancer metastasis. Metabolism alterations of glucose, lipid, and amino acid provide cancer cells with energy and substances for biosynthesis, maintain biofunctions and significantly affect proliferation, invasion, and metastasis of cancer cells. Tumor microenvironment (TME) is a complex system formed by varieties of cellular and noncellular elements. Nontumor cells in TME also undergo metabolic reprogramming or respond to metabolites to promote migration and invasion of cancer cells. A comprehensive understanding of the regulatory mechanism in metastasis from the metabolic reprogramming aspect is required to develop new therapeutic strategies combatting cancer metastasis. This review illustrates the metabolic reprogramming and interaction of cancer cells and nontumor cells in the TME, and the development of treatment strategies targeting metabolism alterations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72128,"journal":{"name":"Aging and cancer","volume":"3 1","pages":"20-43"},"PeriodicalIF":0.0,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aac2.12044","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50805379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信